Biome Australia (BIO) Q1 2027 TU earnings summary

Executive summary

• Q1 FY27 brought record pharmacy sell-through, onshore production commencement, a China distribution agreement and continued BMB18 trial recruitment.

• A second consecutive full-year net profit was reported for FY26; Q1 FY27 generated $100k net operating cash inflow.

Financial highlights

• Customer cash receipts were $6.5m, up 10% QoQ from $5.9m, reflecting sales growth in Australia and international markets.

• Cash was $3.4m at 30 September 2026, down $170k from Q4 FY26; total available funding was $6.5m.

• Product manufacturing and operating cost payments were $2.9m, down 17% YoY; direct brand marketing cash spend was $480k.

Outlook and guidance

• Australian-made Activated Probiotics are expected on pharmacy shelves from November 2026; onshore manufacturing is expected to structurally lower COGS and working capital needs over time.

• China cross-border e-commerce launch remains planned within FY27, subject to a master distribution agreement; volumes, purchase targets and launch date will be confirmed on execution.

• Biome Daily 60 and Biome Daily Kids 60 packs are scheduled to launch in Q2 FY27.